MA39554A2 - - Google Patents
Info
- Publication number
- MA39554A2 MA39554A2 MA39554A MA39554A MA39554A2 MA 39554 A2 MA39554 A2 MA 39554A2 MA 39554 A MA39554 A MA 39554A MA 39554 A MA39554 A MA 39554A MA 39554 A2 MA39554 A2 MA 39554A2
- Authority
- MA
- Morocco
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462024555P | 2014-07-15 | 2014-07-15 | |
US14/797,414 US9902702B2 (en) | 2014-07-15 | 2015-07-13 | Spirocycloheptanes as inhibitors of rock |
PCT/US2015/040254 WO2016010950A1 (fr) | 2014-07-15 | 2015-07-14 | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock |
Publications (3)
Publication Number | Publication Date |
---|---|
MA39554A2 true MA39554A2 (fr) | 2018-01-31 |
MA39554A3 MA39554A3 (fr) | 2019-05-31 |
MA39554B1 MA39554B1 (fr) | 2020-05-29 |
Family
ID=55073996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39554A MA39554B1 (fr) | 2014-07-15 | 2015-07-14 | Spirocycloheptanes utilisés en tant qu'inhibiteurs de rock |
Country Status (24)
Country | Link |
---|---|
US (2) | US9902702B2 (fr) |
EP (1) | EP3169682B1 (fr) |
JP (2) | JP6499749B2 (fr) |
KR (1) | KR102420938B1 (fr) |
CN (1) | CN106817899B (fr) |
AR (1) | AR101208A1 (fr) |
AU (1) | AU2015289897B2 (fr) |
BR (1) | BR112017000808A2 (fr) |
CA (1) | CA2954976A1 (fr) |
CL (1) | CL2017000089A1 (fr) |
CO (1) | CO2017001152A2 (fr) |
EA (1) | EA033061B1 (fr) |
ES (1) | ES2716415T3 (fr) |
IL (1) | IL250046B (fr) |
MA (1) | MA39554B1 (fr) |
MX (1) | MX2017000485A (fr) |
PE (1) | PE20170672A1 (fr) |
PH (1) | PH12017500072A1 (fr) |
SG (1) | SG11201700251PA (fr) |
TN (1) | TN2017000009A1 (fr) |
TW (1) | TW201607933A (fr) |
UY (1) | UY36215A (fr) |
WO (1) | WO2016010950A1 (fr) |
ZA (1) | ZA201700304B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
CN107406426B (zh) | 2015-01-09 | 2020-11-20 | 百时美施贵宝公司 | 作为rock抑制剂的环状脲类 |
US10857157B2 (en) | 2015-01-26 | 2020-12-08 | BioAxone BioSciences, Inc. | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors |
US10106525B2 (en) | 2015-01-26 | 2018-10-23 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
US10112929B2 (en) | 2015-03-09 | 2018-10-30 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
AU2016315648B2 (en) | 2015-08-28 | 2021-04-01 | Chdi Foundation, Inc. | Probes for imaging huntingtin protein |
TWI730032B (zh) * | 2016-01-13 | 2021-06-11 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之螺庚烷水楊酸醯胺及相關化合物 |
WO2017205709A1 (fr) | 2016-05-27 | 2017-11-30 | Bristol-Myers Squibb Company | Utilisation de triazolones et de tétrazolones comme inhibiteurs de la voie de signalisation rho/rock |
US20190256509A1 (en) * | 2016-06-08 | 2019-08-22 | Chrysalis, Inc. | Histone demethylase inhibitors |
US10787450B2 (en) | 2016-07-07 | 2020-09-29 | Bristol-Myers Squibb Company | Spiro-fused cyclic ureas as inhibitors of rock |
ES2814325T3 (es) | 2016-07-07 | 2021-03-26 | Bristol Myers Squibb Co | Derivados de lactama, urea cíclica y carbamato y de triazolona como inhibidores potentes y selectivos de ROCK |
CN109689639B (zh) | 2016-07-07 | 2022-02-18 | 百时美施贵宝公司 | 作为rock抑制剂的螺内酰胺 |
KR102511441B1 (ko) | 2016-11-30 | 2023-03-16 | 브리스톨-마이어스 스큅 컴퍼니 | 트리시클릭 Rho 키나제 억제제 |
WO2018118109A1 (fr) * | 2016-12-21 | 2018-06-28 | BioAxone BioSciences, Inc. | Inhibiteur ba-1049 (r) de rho kinase et ses métabolites actifs |
US11198680B2 (en) | 2016-12-21 | 2021-12-14 | BioAxone BioSciences, Inc. | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof |
CA3047212A1 (fr) * | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Derives de tyrosine amide utilises en tant qu'inhibiteurs de la rho-kinase |
WO2019000683A1 (fr) * | 2017-06-30 | 2019-01-03 | 北京泰德制药股份有限公司 | Inhibiteur de protéine kinase associée à rho, composition pharmaceutique contenant celui-ci, son procédé de préparation et ses applications |
CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
US10537567B2 (en) | 2017-07-11 | 2020-01-21 | BioAxone BioSciences, Inc. | Kinase inhibitors for treatment of disease |
JP7313331B2 (ja) * | 2017-07-12 | 2023-07-24 | ブリストル-マイヤーズ スクイブ カンパニー | Rock阻害剤としてのスピロヘプタニルヒダントイン |
US11299488B2 (en) | 2017-07-12 | 2022-04-12 | Bristol-Myers Squibb Company | Five membered-aminoheterocycle and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure |
TW201908293A (zh) | 2017-07-12 | 2019-03-01 | 美商必治妥美雅史谷比公司 | 作為rock抑制劑之5員及雙環雜環醯胺 |
US11306081B2 (en) | 2017-07-12 | 2022-04-19 | Bristol-Myers Squibb Company | Phenylacetamides as inhibitors of rock |
SG11202000839TA (en) | 2017-08-14 | 2020-02-27 | Epizyme Inc | Methods of treating cancer by inhibiting setd2 |
US11542256B2 (en) | 2017-09-03 | 2023-01-03 | Angion Biomedica Corp. | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
ES2937039T3 (es) | 2017-11-03 | 2023-03-23 | Bristol Myers Squibb Co | Inhibidores diazaespiro de ROCK |
JP2021536428A (ja) * | 2018-08-14 | 2021-12-27 | エピザイム,インコーポレイティド | 置換インドール及びその使用方法 |
JP7367004B2 (ja) * | 2018-09-06 | 2023-10-23 | エフ. ホフマン-ラ ロシュ アーゲー | 自己免疫疾患の処置のための新規のピラゾロビリジン化合物 |
LT3999038T (lt) * | 2019-07-17 | 2024-03-25 | Cytokinetics, Inc. | Širdies sarkomerų inhibitoriaus geriamosios vaistinės formos |
WO2021257857A1 (fr) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f |
WO2021257863A1 (fr) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2 |
US11780840B2 (en) | 2020-07-02 | 2023-10-10 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
WO2022006456A1 (fr) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Composés de pyridone tricyclique en tant qu'inhibiteurs de v617f de jak2 |
TW202211917A (zh) * | 2020-08-21 | 2022-04-01 | 南韓商治納輔醫藥科技有限公司 | 對前列腺素e2受體具有抑制活性的新穎化合物及其用途 |
WO2022046989A1 (fr) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Composés d'urée tricycliques en tant qu'inhibiteurs de v617f de jak2 |
JP2023550260A (ja) * | 2020-11-25 | 2023-12-01 | エフ. ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス感染症の処置および予防のための芳香族スピロ環アミド誘導体 |
US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為jak2 v617f抑制劑之螺環內醯胺 |
WO2022237878A1 (fr) * | 2021-05-14 | 2022-11-17 | 武汉朗来科技发展有限公司 | Forme cristalline de composé, composition contenant la forme cristalline, son procédé de préparation et son utilisation |
CN113861223B (zh) * | 2021-09-07 | 2022-09-16 | 暨南大学 | 一种噻唑并[3,2-a]苯并咪唑类化合物的合成方法及其应用 |
WO2023187182A1 (fr) * | 2022-04-01 | 2023-10-05 | Sanofi | Composés de pyrazolopyrazinone, leur procédé de préparation et leurs utilisations thérapeutiques |
TW202402269A (zh) * | 2022-05-26 | 2024-01-16 | 大陸商迪哲(江蘇)醫藥股份有限公司 | ROCK(Rho相關激酶)抑制劑及其用途 |
CN115894141B (zh) * | 2022-10-13 | 2023-12-22 | 贺州学院 | 酰基茚烷类衍生物的合成方法 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2531776A1 (de) | 1975-07-16 | 1977-02-03 | Basf Ag | Azopigmente mit einem phthalazonrest |
TW245719B (fr) | 1990-09-10 | 1995-04-21 | Sterling Winthrop Inc | |
EP0481383B1 (fr) | 1990-10-16 | 1995-06-28 | Takeda Chemical Industries, Ltd. | Dérivés hétérocycliques des amines, leur production et leur utilisation |
EP0634402A1 (fr) | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Dérivés d'isoquinolinone, leur production et utilisation |
AU6230098A (en) | 1997-02-27 | 1998-09-18 | Tanabe Seiyaku Co., Ltd. | Isoquinolinone derivatives, process for preparing the same, and their use as phosphodiesterase inhibitors |
DE19804085A1 (de) | 1998-02-03 | 1999-08-05 | Boehringer Ingelheim Pharma | 5-Gliedrige heterocyclische kondensierte Benzoderivate, deren Herstellung und deren Verwendung als Arzneimittel |
EP1060166A1 (fr) | 1998-02-03 | 2000-12-20 | Boehringer Ingelheim Pharma KG | Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques |
JP2000072675A (ja) | 1998-08-26 | 2000-03-07 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
KR20010101675A (ko) | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2h-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
DE19907813A1 (de) | 1999-02-24 | 2000-08-31 | Boehringer Ingelheim Pharma | Substituierte bicyclische Heterocyclen, deren Herstellung und deren Verwendung als Arzneimittel |
BR0115062A (pt) | 2000-10-30 | 2004-02-17 | Kudos Pharm Ltd | Derivados de ftalazinona |
CA2476162A1 (fr) | 2002-02-13 | 2003-08-21 | Takeda Chemical Industries, Ltd. | Inhibiteur de jnk |
JPWO2004024694A1 (ja) | 2002-09-10 | 2006-01-05 | 杏林製薬株式会社 | 4−置換アリール−5−ヒドロキシイソキノリノン誘導体 |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
WO2006036981A2 (fr) | 2004-09-28 | 2006-04-06 | Angion Biomedica Corp. | Petits modulateurs moleculaires de l'activite de cytokines |
WO2006124874A2 (fr) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibiteurs de la b-raf kinase |
CN101296904A (zh) * | 2005-07-11 | 2008-10-29 | 德福根有限公司 | 作为激酶抑制剂的酰胺衍生物 |
EP2032562B1 (fr) * | 2006-05-12 | 2010-08-25 | Vertex Pharmaceuticals Incorporated | Inhibiteurs sélectifs de protéine kinase rock et utilisations de ceux-ci |
RU2008152065A (ru) * | 2006-06-08 | 2010-07-20 | Убе Индастриз, Лтд (Jp) | Новое производное имидазола со спироциклической структурой в боковой цепи |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
AU2007338407B2 (en) * | 2006-12-27 | 2012-08-02 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone derivatives |
CL2007003874A1 (es) | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
WO2009064422A2 (fr) | 2007-11-13 | 2009-05-22 | Angion Biomedica Corp. | Activateurs des voies du facteur de croissance hépatocytaire dans les maladies des tissus conjonctifs fibrotiques |
WO2011019400A2 (fr) | 2009-08-12 | 2011-02-17 | Angion Biomedica Corp. | Amélioration dune transplantation cellulaire en utilisant des modulateurs à petite molécule de lactivité de facteur de croissance dhépatocyte (scatter factor) |
US9302989B2 (en) | 2010-11-15 | 2016-04-05 | Abbvie Inc. | NAMPT and rock inhibitors |
CN102485721B (zh) | 2010-12-03 | 2015-12-09 | 曹亚 | 取代的2,3-二氮杂萘酮化合物及其用途 |
CN102180909B (zh) | 2011-03-18 | 2014-10-22 | 南京邮电大学 | 以酞嗪衍生物为配体的铱配合物磷光材料及其制备方法 |
CN102327275B (zh) * | 2011-09-07 | 2013-03-20 | 苏州大学 | 3-[4-(磺酰)苯]脲类化合物在制备抗肿瘤药物中的应用 |
CN102432612B (zh) * | 2011-09-07 | 2014-09-17 | 苏州大学 | 4,7-二氢四唑[1,5-a]嘧啶衍生物及其在制备抗肿瘤药物中的应用 |
WO2014079850A1 (fr) | 2012-11-23 | 2014-05-30 | F. Hoffmann-La Roche Ag | Dérivés hétérocycliques substitués |
EP3252050B1 (fr) | 2013-01-18 | 2020-02-26 | Bristol-Myers Squibb Company | Phthalazinones et isoquinolinones utilisées comme inhibiteurs de roche |
WO2014134391A1 (fr) | 2013-02-28 | 2014-09-04 | Bristol-Myers Squibb Company | Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2 |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
US9102684B2 (en) * | 2013-03-27 | 2015-08-11 | Boehringer Ingelheim International Gmbh | Indolinone analogues |
CN103242647B (zh) | 2013-04-27 | 2015-06-17 | 大连理工大学 | 一种阻燃耐热聚氨酯泡沫塑料及其制备方法 |
ES2633987T3 (es) | 2013-07-02 | 2017-09-26 | Bristol-Myers Squibb Company | Derivados de pirido-carboxamidas tricíclicas como inhibidores de ROCK |
EP3016950B1 (fr) | 2013-07-02 | 2017-06-07 | Bristol-Myers Squibb Company | Dérivés de pyrido-carboxamides tricycliques en tant qu' inhibiteurs du rock |
CA2935270A1 (fr) | 2014-01-20 | 2015-07-23 | F. Hoffmann-La Roche Ag | Derives de n-phenyl-lactame capables de stimuler la neurogenese et leur utilisation dans le traitement de troubles neurologiques |
US9902702B2 (en) * | 2014-07-15 | 2018-02-27 | Bristol-Myers Squibb Company | Spirocycloheptanes as inhibitors of rock |
-
2015
- 2015-07-13 US US14/797,414 patent/US9902702B2/en active Active
- 2015-07-14 WO PCT/US2015/040254 patent/WO2016010950A1/fr active Application Filing
- 2015-07-14 TN TN2017000009A patent/TN2017000009A1/en unknown
- 2015-07-14 AU AU2015289897A patent/AU2015289897B2/en active Active
- 2015-07-14 KR KR1020177003772A patent/KR102420938B1/ko active IP Right Grant
- 2015-07-14 BR BR112017000808A patent/BR112017000808A2/pt not_active Application Discontinuation
- 2015-07-14 UY UY0001036215A patent/UY36215A/es unknown
- 2015-07-14 JP JP2017502166A patent/JP6499749B2/ja active Active
- 2015-07-14 AR ARP150102245A patent/AR101208A1/es unknown
- 2015-07-14 CN CN201580049090.6A patent/CN106817899B/zh active Active
- 2015-07-14 ES ES15742478T patent/ES2716415T3/es active Active
- 2015-07-14 TW TW104122821A patent/TW201607933A/zh unknown
- 2015-07-14 CA CA2954976A patent/CA2954976A1/fr active Pending
- 2015-07-14 MA MA39554A patent/MA39554B1/fr unknown
- 2015-07-14 EA EA201790062A patent/EA033061B1/ru not_active IP Right Cessation
- 2015-07-14 MX MX2017000485A patent/MX2017000485A/es active IP Right Grant
- 2015-07-14 PE PE2017000041A patent/PE20170672A1/es unknown
- 2015-07-14 SG SG11201700251PA patent/SG11201700251PA/en unknown
- 2015-07-14 EP EP15742478.9A patent/EP3169682B1/fr active Active
-
2017
- 2017-01-10 IL IL250046A patent/IL250046B/en active IP Right Grant
- 2017-01-11 PH PH12017500072A patent/PH12017500072A1/en unknown
- 2017-01-13 CL CL2017000089A patent/CL2017000089A1/es unknown
- 2017-01-13 ZA ZA2017/00304A patent/ZA201700304B/en unknown
- 2017-02-07 CO CONC2017/0001152A patent/CO2017001152A2/es unknown
-
2018
- 2018-02-01 US US15/886,426 patent/US20180155296A1/en not_active Abandoned
-
2019
- 2019-03-15 JP JP2019048151A patent/JP6721741B2/ja active Active